Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons.
Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Verheust C, Dezutter N, Gruselle O, Fissette L, David MP, Kostanyan L, Hulstrøm V, Olivier A, Van der Wielen M, Descamps D; AReSVi-006 study group. Ison MG, et al. Clin Infect Dis. 2024 Jan 22:ciae010. doi: 10.1093/cid/ciae010. Online ahead of print. Clin Infect Dis. 2024. PMID: 38253338
Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin's lymphoma: results from the randomized international GHSG HD18 trial.
Ferdinandus J, Müller H, Damaschin C, Jacob AS, Meissner J, Krasniqi F, Mey U, Schöndube D, Thiemer J, Mathas S, Zijlstra J, Greil R, Feuring-Buske M, Markova J, Rüffer JU, Kobe C, Eich HT, Baues C, Fuchs M, Borchmann P, Behringer K. Ferdinandus J, et al. Ann Oncol. 2024 Mar;35(3):276-284. doi: 10.1016/j.annonc.2023.11.014. Epub 2023 Dec 5. Ann Oncol. 2024. PMID: 38061428 Free article.
68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial.
Kessler L, Hirmas N, Pabst KM, Hamacher R, Ferdinandus J, Schaarschmidt BM, Milosevic A, Nader M, Umutlu L, Uhl W, Reinacher-Schick A, Lugnier C, Witte D, Niedergethmann M, Herrmann K, Fendler WP, Siveke JT. Kessler L, et al. J Nucl Med. 2023 Dec 1;64(12):1910-1917. doi: 10.2967/jnumed.122.264827. J Nucl Med. 2023. PMID: 37973185
Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin's lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study Group.
Ferdinandus J, van Heek L, Roth K, Dietlein M, Eich HT, Baues C, Borchmann P, Kobe C. Ferdinandus J, et al. Eur J Nucl Med Mol Imaging. 2024 Jan;51(2):490-495. doi: 10.1007/s00259-023-06431-w. Epub 2023 Sep 22. Eur J Nucl Med Mol Imaging. 2024. PMID: 37735258 Free PMC article. Clinical Trial.
Prognostic value of baseline metabolic tumor volume (MTV) for forecasting chemotherapy outcome in early-stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trial.
van Heek L, Weindler J, Gorniak C, Kaul H, Müller H, Mettler J, Baues C, Fuchs M, Borchmann P, Ferdinandus J, Dietlein M, Voltin CA, Kobe C, Roth KS. van Heek L, et al. Eur J Haematol. 2023 Dec;111(6):881-887. doi: 10.1111/ejh.14093. Epub 2023 Aug 29. Eur J Haematol. 2023. PMID: 37644732
75 results